SplitJul 17, 2026, 04:37 PM
Valion Bio Proposes Reverse Stock Split to Maintain Nasdaq Listing
AI Summary
Valion Bio, Inc. announced a Special Meeting of Stockholders on August 14, 2026, to vote on a proposal to authorize a reverse stock split. The proposed split ratio would be between 1-for-5 and 1-for-50, at the discretion of the Board. The primary reason for this action is to regain compliance with Nasdaq's minimum bid price requirement, following a deficiency notice received on March 19, 2026. The Board unanimously recommends stockholders approve the proposal.
Key Highlights
- Special Meeting of Stockholders scheduled for August 14, 2026.
- Proposal to authorize a reverse stock split at a ratio of 1-for-5 to 1-for-50.
- Primary purpose is to regain compliance with Nasdaq's $1.00 minimum bid price requirement.
- Company received a Nasdaq deficiency letter on March 19, 2026.
- Board of Directors unanimously recommends voting "FOR" the reverse stock split.
- As of July 7, 2026, 4,151,259 shares of Common Stock were outstanding.
Price Impact
More from TIVC